Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

(2021) A. Armstrong et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis

(2020) Jashin J. Wu et al.   ADVANCES IN THERAPY

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

(2020) Miguel Nogueira et al.   DRUGS

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

(2020) April W. Armstrong et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Philip J Mease et al.   LANCET

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Atul Deodhar et al.   LANCET

Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies

(2020) Chao-Ran Li   International Journal of Ophthalmology

Mortality in psoriatic arthritis: Risk, causes of death, predictors for death

(2020) Ofir Elalouf et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Janus kinases to jakinibs: from basic insights to clinical practice

(2019) Massimo Gadina et al.   RHEUMATOLOGY

Psoriatic arthritis for dermatologists

(2019) Alice Gottlieb et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Selective activation of TWIK-related acid-sensitive K+ 3 subunit–containing channels is analgesic in rodent models

(2019) Ping Liao et al.   Science Translational Medicine

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

(2018) Kim Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Psoriatic Arthritis

(2017) Christopher T. Ritchlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

(2016) Jacqueline B. Palmer et al.   BMC MUSCULOSKELETAL DISORDERS

Psoriasis

(2016) Jacqueline E. Greb et al.   Nature Reviews Disease Primers

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis

(2014) Philip J. Mease et al.   DRUGS